
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.
The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...





